Medexus Pharmaceuticals Inc.
MEDXF
$1.77
-$0.01-0.56%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 109.54M | 104.76M | 108.78M | 113.05M | 115.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.54M | 104.76M | 108.78M | 113.05M | 115.73M |
| Cost of Revenue | 46.13M | 44.15M | 46.15M | 47.99M | 48.91M |
| Gross Profit | 63.41M | 60.61M | 62.63M | 65.07M | 66.81M |
| SG&A Expenses | 41.38M | 41.10M | 43.32M | 44.87M | 45.89M |
| Depreciation & Amortization | 6.19M | 5.88M | 5.77M | 5.81M | 5.84M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 94.50M | 91.94M | 96.51M | 100.27M | 102.94M |
| Operating Income | 15.04M | 12.82M | 12.28M | 12.79M | 12.79M |
| Income Before Tax | 3.19M | 1.51M | 1.12M | 106.00K | -872.00K |
| Income Tax Expenses | -373.00K | -781.00K | 30.00K | 320.00K | -6.75M |
| Earnings from Continuing Operations | 3.56 | 2.30 | 1.09 | -0.21 | 5.88 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.56M | 2.30M | 1.09M | -214.00K | 5.88M |
| EBIT | 15.04M | 12.82M | 12.28M | 12.79M | 12.79M |
| EBITDA | 21.15M | 18.63M | 17.97M | 18.55M | 18.44M |
| EPS Basic | 0.15 | 0.09 | 0.04 | -0.01 | 0.30 |
| Normalized Basic EPS | 0.20 | 0.16 | 0.08 | 0.05 | -0.02 |
| EPS Diluted | 0.15 | 0.09 | 0.04 | -0.01 | 0.26 |
| Normalized Diluted EPS | 0.20 | 0.16 | 0.08 | 0.05 | -0.02 |
| Average Basic Shares Outstanding | 98.13M | 97.64M | 93.53M | 89.30M | 84.78M |
| Average Diluted Shares Outstanding | 98.79M | 98.30M | 94.19M | 89.96M | 86.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |